More vaccines enter Phase III trials, researchers continue to learn about the long-term impacts of Covid-19, and risk calculation becomes increasingly difficult as the country reopens. Here’s your week in coronavirus news:
Want to receive this weekly roundup and other coronavirus news? Sign up here!
The race for a vaccine continues at warp speed
When it comes to vaccine development, there are two big issues on the table, according to WIRED’s Adam Rogers. First you need to develop a safe vaccine that works. Then “you need a communications strategy that explains exactly what the drug does and how it does it” so that people trust the vaccine enough to go get it.
This week, there was plenty of hopeful news related to the first issue. New research found that a century-old tuberculosis shot could help protect against Covid-19, though more research is underway and won’t be completed until early 2021. Meanwhile, two more vaccines, from Novovax and Johnson & Johnson, entered Phase III trials. Unlike its competitors, the Johnson & Johnson vaccine doesn’t need to be frozen and requires only one dose, giving it a leg up. In all likelihood, there will eventually be several viable vaccines, all of which will be necessary to make sure everyone is protected worldwide. Though, as Roxanne Khamsi notes, the fact that most vaccines are being developed in wealthy countries means they might not work as well for people from poorer nations.
Once Americans have a vaccine, how will the public know it’s safe? The question is on everyone’s mind. A new survey from the Pew Research Center found that just 51 percent of US adults say they would get a Covid-19 vaccine if it were available today, compared to 72 percent in May. Earlier this week, a group of Black physicians as well as New York governor Andrew Cuomo said they intend to independently vet the vaccines that earn government approval. In an attempt to restore public trust, the FDA announced a plan to issue stricter guidelines for vaccine authorization earlier this week, which will effectively eliminate the possibility of a vaccine before November 3. President Trump chalked the move up to politics.
Researchers are learning more about the long-term impact of Covid-19
As the pandemic progresses, researchers continue to better understand the mysterious consequences of Covid-19. Reddit threads, Facebook pages, and other online support groups have proliferated as a resource both for people recovering from the disease and the scientists trying to figure it out. Without the ability to open labs and collect data in person, even the most common symptoms have proven difficult to fully understand. For example, we still know very little about Covid-induced anosmia. Researchers have sent out surveys and created diagnostic tools to help patients track smell loss, but there’s a lot that will be difficult to study until people can get in a room together.
On the other hand, all the humans being on lockdown has allowed ecologists to gain unprecedented access to other species. A new study reports that male white-crowned sparrows in the San Francisco Bay Area changed their tune in April and May. Previously, the birds sacrificed song quality for volume, yelling to be heard in a noisy world. But once it quieted down, they switched to a softer, higher-quality call.
New tools aim to help you calculate risk as cases rise and the country reopens
This week, the death toll in the US surpassed 200,000 as weekly new cases rose for the second week in a row. Still, the country’s nonlinear path toward reopening continues. In the absence of reliable guidelines, we’ve all had to figure out how to calculate coronavirus risk for ourselves every time we step outside. Vox’s Ezra Klein recently described the equation as follows: “The danger of an act = (the transmission risk of the activity) x (the local prevalence of Covid-19) / (by your area’s ability to control a new outbreak).”